Equities analysts forecast that AbbVie Inc (NYSE:ABBV) will report sales of $7.56 billion for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for AbbVie’s earnings, with the lowest sales estimate coming in at $7.51 billion and the highest estimate coming in at $7.63 billion. AbbVie posted sales of $6.80 billion in the same quarter last year, which suggests a positive year-over-year growth rate of 11.2%. The firm is scheduled to issue its next earnings results on Friday, January 26th.

According to Zacks, analysts expect that AbbVie will report full-year sales of $7.56 billion for the current fiscal year, with estimates ranging from $27.88 billion to $28.11 billion. For the next financial year, analysts forecast that the company will post sales of $31.31 billion per share, with estimates ranging from $30.77 billion to $32.63 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that cover AbbVie.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 27th. The company reported $1.41 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.39 by $0.02. The company had revenue of $7 billion for the quarter, compared to analysts’ expectations of $7 billion. AbbVie had a return on equity of 153.80% and a net margin of 24.38%. AbbVie’s quarterly revenue was up 8.8% on a year-over-year basis. During the same period last year, the firm earned $1.21 earnings per share.

Several analysts have weighed in on ABBV shares. Societe Generale lifted their price objective on AbbVie in a research report on Tuesday, November 21st. Jefferies Group reaffirmed a “buy” rating and set a $107.00 price objective (up from $94.00) on shares of AbbVie in a research report on Friday, September 15th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $100.00 price objective on shares of AbbVie in a research report on Friday, September 15th. SunTrust Banks reaffirmed a “buy” rating and set a $95.00 price objective on shares of AbbVie in a research report on Wednesday, September 13th. Finally, Goldman Sachs Group reaffirmed a “buy” rating and set a $100.00 price objective (up from $85.00) on shares of AbbVie in a research report on Friday, September 8th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $97.96.

Shares of AbbVie (NYSE:ABBV) opened at $97.35 on Thursday. The company has a quick ratio of 1.32, a current ratio of 1.45 and a debt-to-equity ratio of 5.08. The stock has a market capitalization of $153,736.20, a PE ratio of 18.14, a P/E/G ratio of 1.34 and a beta of 1.52. AbbVie has a 12 month low of $59.27 and a 12 month high of $98.87.

The business also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be given a $0.71 dividend. This is a boost from AbbVie’s previous quarterly dividend of $0.64. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.92%. The ex-dividend date is Thursday, January 11th. AbbVie’s payout ratio is currently 62.29%.

In related news, Chairman Richard A. Gonzalez sold 218,193 shares of the business’s stock in a transaction that occurred on Tuesday, November 21st. The shares were sold at an average price of $94.01, for a total value of $20,512,323.93. Following the completion of the transaction, the chairman now directly owns 492,030 shares in the company, valued at approximately $46,255,740.30. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Robert A. Michael sold 6,699 shares of the business’s stock in a transaction that occurred on Thursday, September 28th. The stock was sold at an average price of $88.00, for a total transaction of $589,512.00. Following the completion of the transaction, the vice president now owns 10,007 shares of the company’s stock, valued at $880,616. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 268,825 shares of company stock valued at $25,186,090. 0.23% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in ABBV. Formidable Asset Management LLC increased its stake in shares of AbbVie by 0.3% in the 2nd quarter. Formidable Asset Management LLC now owns 3,926 shares of the company’s stock worth $285,000 after purchasing an additional 10 shares in the last quarter. WealthTrust Axiom LLC boosted its holdings in AbbVie by 0.3% in the 2nd quarter. WealthTrust Axiom LLC now owns 4,307 shares of the company’s stock worth $312,000 after buying an additional 15 shares during the period. Abner Herrman & Brock LLC boosted its holdings in AbbVie by 0.3% in the 2nd quarter. Abner Herrman & Brock LLC now owns 6,293 shares of the company’s stock worth $456,000 after buying an additional 18 shares during the period. Bollard Group LLC boosted its holdings in AbbVie by 0.5% in the 2nd quarter. Bollard Group LLC now owns 3,764 shares of the company’s stock worth $273,000 after buying an additional 19 shares during the period. Finally, St. Louis Trust Co boosted its holdings in AbbVie by 0.7% in the 2nd quarter. St. Louis Trust Co now owns 3,411 shares of the company’s stock worth $248,000 after buying an additional 23 shares during the period. Institutional investors and hedge funds own 69.32% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/12/14/zacks-analysts-anticipate-abbvie-inc-abbv-will-post-quarterly-sales-of-7-56-billion.html.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Get a free copy of the Zacks research report on AbbVie (ABBV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.